University of Texas-MD Anderson Cancer Center: Targeted Therapy Erdafitinib Effective for Patients With Advanced Bladder Cancer, Specific Gene Mutations
July 24, 2019
July 24, 2019
HOUSTON, Texas, July 24 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
* * *
Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, accord . . .
* * *
- FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
* * *
Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, accord . . .